Moderna stock falls after earnings as FDA decision approaches
Moderna shares came under pressure following the company's quarterly earnings release, despite results that exceeded analysts' expectations.
Moderna reported a loss of $1.97 per share, compared with analysts' expectations for a loss of approximately $2.04 per share. Revenue totaled $145 million, comfortably beating the consensus estimate of $103.9 million. However, investors were disappointed by a 63% decline in revenue compared with the previous quarter.
At the same time, Moderna reaffirmed its 2026 revenue growth guidance of up to 10% and improved its operating expense outlook. Even so, investors remain focused on the pace of commercialization for the company's new products and its ability to offset declining COVID-19 vaccine sales across certain markets.

Gap down shifts focus to key support
A gap down has formed in premarket trading, making long positions against the direction of the gap unattractive at this stage.The key support level is located around $51.80. If sellers establish a sustained move below this level, the probability of a decline toward the 200-day SMA near $44.70 will increase.
Today's trading session is likely to remain highly volatile. If the stock manages to hold above $55, Moderna shares could attempt a recovery toward $60.